Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod 5% Cream in Pediatric Plaque Morphea
NCT00147771Phase 3Completed
- Sponsor
- SickKids
- Start
- Sep 2005
- Primary completion
- Sep 2009
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imiquimod in morphea, sponsored by SickKids. Primary endpoint: Percent improvement in the thickness of the skin at 48 weeks. Started Sep 2005; status: completed.
02
Drugs
imiquimod
03
Conditions
morphea
Beyond the preview
Go deeper on NCT00147771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147771.